Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Is COVID-19 infection more severe in kidney transplant recipients?

Sophie Caillard | Nathalie Chavarot | Hélène Francois | Marie Matignon | Clarisse Greze | Nassim Kamar | Philippe Gatault | Olivier Thaunat | Tristan Legris | Luc Frimat | Pierre F. Westeel | Valentin Goutaudier | Mariam Jdidou | Renaud Snaoudi | Charlotte Colsio | Antoine Sicard | Dominique Bertrand | Christiane Mousson | Jamel Bamouild | Christophe Masset | Antoine Thierry | Lionel Couzi | Jonathan M. Chemouny | Agnes Duveau | Valerie Moa | Gilles Blancho | Philippe Grimbert | Antoine Durrbach | Bruno Moulin | Dany Anglicheau | Yvon Ruch | Charlotte Kaeuffer | Ilies Benotmane | Morgane Solis | Yannick LeMeur | Marc Haazan | Francois Danion | on behalf of the French SOT COVID Registry

1Department of Nephrology and Transplantation, Strasbourg University Hospital, INSERM, UMR-S 1109, Strasbourg, France
2Department of Nephrology and Transplantation, Hôpital Universitaire Necker, APHP Center, Université de Paris INEM INSERM U 1151, CNRS UMR 8253, Paris, France
3AP-HP (Assistance Publique-Hôpitaux de Paris), Department of Nephrology and Transplantation, Hopital Tenon, Paris, France
4AP-HP, Nephrology and Renal Transplantation Department, Institut Francilien de Recherche en Néphrologie et Transplantation (IFRNT), Groupe Hospitalier Henri-Mondor/Albert-Chezard, Université Paris-Est-Créteil, (UPEC), DHU (Département Hospitalo-Universitaire) VIC (Virus-Immunité-Cancer), IMRB (Institut Mondor de Recherche Biomédicale), Equipe 21, INSERM U 955, Créteil, France
5Department of Nephrology and Transplantation, Hôpital Bichat, Paris, France
6Department of Nephrology and Transplantation, University of Toulouse, Toulouse, France
7Department of Nephrology and Transplantation, University of Tours, Tours, France
8Department of Transplantation, Nephrology and Clinical Immunology, Hôpital Edouard Herriot, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon, France
9Aix Marseille Université, Hôpitaux Universitaires de Marseille, Hôpital Conception, Centre de Néphrologie et Transplantation Rénale, Marseille, France
10Department of Nephrology, University of Lorraine, CHRU-Nancy, Vandoeuvre, France
11INSERM CIC-EC CIE6, Nancy, France
12Department of Nephrology and Transplantation, University of Amiens, Amiens, France
13Department of Nephrology and Transplantation, University of Montpellier, Montpellier, France
14Department of Nephrology and Transplantation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
15Department of Nephrology and Transplantation, University of Reims, Reims, France
16Department of Nephrology, Dialysis, and Transplantation, Hopital Pasteur 2, C.H.U. de Nice, Unité de Recherche Clinique Côte d'Azur (UR2CA), Université Côte d'Azur, Nice, France
17Department of Nephrology and Transplantation, University of Rouen, Rouen, France
18Department of Nephrology and Transplantation, University of Dijon, Dijon, France
19Department of Nephrology, University of Besançon, Besançon, France
20Department of Nephrology and Transplantation, Center Hospitalier Universitaire de Nantes, Nantes, France
21Department of Nephrology, University of Poitiers, Poitiers, France
22Department of Nephrology-Transplantation-Dialysis-Apheresis, Hôpital Pellegrin, CHU de Bordeaux Pellegrin, Unité Mixte de Recherche "ImmunoConcEpT" 5164 – Université de Bordeaux, Bordeaux, France

Marc Haazan and Francois Danion contributed equally to this work.

© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons
There are no studies which have compared the risk of severe COVID-19 and related mortality between transplant recipients and nontransplant patients. We enrolled two groups of patients hospitalized for COVID-19, that is, kidney transplant recipients (KTR) from the French Registry of Solid Organ Transplant (n = 306) and a single-center cohort of nontransplant patients (n = 795). An analysis was performed among subgroups matched for age and risk factors for severe COVID-19 or mortality. Severe COVID-19 was defined as admission (or transfer) to an intensive care unit, need for mechanical ventilation, or death. Transplant recipients were younger and had more comorbidities compared to nontransplant patients. They presented with higher creatinine levels and developed more episodes of acute kidney injury. After matching, the 30-day cumulative incidence of severe COVID-19 did not differ between KTR and nontransplant patients; however, 30-day COVID-19-related mortality was significantly higher in KTR (17.9% vs 11.4%, respectively, p = .038). Age >60 years, cardiovascular disease, dyspnea, fever, lymphopenia, and C-reactive protein (CRP) were associated with severe COVID-19 in univariate analysis, whereas transplant status and serum creatinine levels were not. Age >60 years, hypertension, cardiovascular disease, diabetes, CRP >60 mg/L, lymphopenia, kidney transplant status (HR = 1.55), and creatinine level >115 µmol/L (HR = 2.32) were associated with COVID-19-related mortality in univariate analysis. In multivariable analysis, cardiovascular disease, dyspnea, and fever were associated with severe disease, whereas age >60 years, cardiovascular disease, dyspnea, fever, and creatinine level >115 µmol/L retained their independent associations with mortality. KTR had a higher COVID-19-related mortality compared to nontransplant hospitalized patients.

**KEYWORDS**
cardiovascular disease, clinical research / practice, glomerular filtration rate (GFR), immunosuppressive regimens, infection and infectious agents - viral, infectious disease, kidney failure / injury, kidney transplantation / nephrology

1 | INTRODUCTION

Prior experience with respiratory viruses in patients who had undergone solid organ transplantation revealed how recipients have greater susceptibility, more rapid progression to pneumonia, greater disease severity, and prolonged viral shedding compared with nontransplant hosts. In light of past coronavirus outbreaks, COVID-19 poses a significant threat for immunocompromised patients, and transplant physicians are particularly concerned about the impact of this new infection on this frail population. Single-center studies have reported a high mortality rate in kidney transplant recipients (KTR) with COVID-19. There is also evidence that at least part of COVID-19’s severity is linked to the “cytokine storm,” which is a disproportionate hyperinflammatory reaction occurring in infected patients. In this scenario, immunosuppressive drugs may be clinically useful in reducing this dysfunctional immune response by attenuating the positive feedback loop typical of the cytokine release syndrome (CRS). Nonetheless, the question as to whether KTR would actually exhibit a higher risk of severe COVID-19 or—alternatively—immunosuppression would protect them from CRS and critical forms of the disease remains unanswered.
Chronic kidney disease and acute kidney injury (AKI) have been reported to affect the prognosis of patients hospitalized for COVID-19. Notably, KTR are in an immunosuppressed state with concurrent chronic kidney disease and are particularly susceptible to AKI. Starting from these premises, this research was undertaken to determine how these factors may influence the clinical outcomes of KTR with COVID-19. We also compared the prognosis of COVID-19 in KTR and nontransplant patients by using data from a French nationwide registry.

2 | PATIENTS AND METHODS

A cohort of KTR hospitalized for COVID-19 was identified from a multicenter nationwide French Registry—termed French SOT COVID—between March 1 and April 30, 2020. Inclusion criteria were age >18 years at the diagnosis of COVID-19 and presence of a functioning graft. The control group consisted of nontransplant adult patients with confirmed COVID-19 who were hospitalized at the Strasbourg University Hospital between March 1 and March 31, 2020. Cases with a history of immunosuppression (previous transplantation; patients on high-dose steroids, immunosuppressive drugs, or biological therapies in the month preceding hospitalization; those with primary immune deficiency; and those with previous splenectomy) were excluded from the control group. The diagnostic criteria for COVID-19 were as follows: (1) severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection determined by reverse transcriptase-polymerase chain reaction (RT-PCR) testing of nasopharyngeal swab specimens, or (2) presence of typical respiratory symptoms associated with evocative pulmonary lesions on low-dose chest computed tomography (CT) when RT-PCR yielded negative results. AKI was defined according to the Kidney Disease Improving Global Outcomes guidelines. Severe COVID-19 was defined as admission (or transfer) to an intensive care unit (ICU), need for mechanical ventilation, or death. All other patients were considered as nonsevere cases. Ethical approval for the creation of transplant recipients and nontransplant patients were plotted with the Kaplan–Meier method and compared using the log-rank test. Cox proportional hazards univariable and multivariable models were constructed using a backward-conditional selection procedure to identify predictors of the study endpoints. The optimal model was selected according to the highest concordance (Harrel’s C statistic) value. Results are expressed as hazard ratios (HRs) with their 95% confidence intervals (CIs). Matching was performed by selection of nearest neighbor best control matches for each individual in the KTR group. Patients were matched in a 1:1 ratio using the logit of the estimated propensity of being in the transplant group as the distance metric. Age, BMI, cardiovascular and respiratory diseases, cancer, and diabetes were included as covariates in the propensity score model because these variables are the main risk factors for COVID-19. A caliper (0.3) was set for age only. There were 33 transplant recipients who could not be matched to a nontransplant patient. Tabular data for matched cohorts are reported as standardized mean differences with their 95% CIs. All analyses were undertaken in the R environment (R Foundation for Statistical Computing, Vienna, Austria). A value of \( p < .05 \) (two-tailed) was considered statistically significant.

3 | RESULTS

A total of 306 KTR were included in the SOT COVID Registry at the time of this analysis. The median recipient age was 62 years (IQR: 52–69 years) and 67.6% were men. The median time between transplantation and COVID-19 diagnosis was 74.6 months (IQR: 27.8–140.6 months), and only 12% of all KTR were in the first posttransplant year at the time of COVID-19 diagnosis. Immunosuppressive drugs used at baseline and management of immunosuppression at the time of COVID-19 diagnosis are summarized in Table S1. The control cohort consisted of 795 nontransplant patients with COVID-19 (median age: 69 years, IQR: 57–79 years; 58.6% men). The characteristics of the two study groups are reported in Table S2. KTR were younger, more commonly male, and had lower body mass index (BMI) but had more comorbidities (hypertension, cardiovascular diseases, respiratory diseases, and diabetes). They less frequently exhibited dyspnea during admission for COVID-19, but more commonly had fever and diarrhea than nontransplant patients. Of note, the median time from symptom onset to admission was shorter among KTR than nontransplant patients (5 vs 7 days, respectively, \( p = .006 \)). KTR displayed a less severe inflammatory syndrome, a more profound lymphopenia, and a higher creatinine level at admission (176 µmol/L vs 75 µmol/L, respectively, \( p < .001 \)). Infection management was slightly different, with antibiotics and azithromycin more frequently used in nontransplant patients, in contrast to more antifungal drugs (4.6% vs 2.1%, respectively, \( p = .028 \)), fewer specific antivirals (lopinavir/ritonavir 5.2% vs 21.8%, respectively, \( p < .01 \)), and more frequent tocilizumab (5.6% vs 1%, respectively, \( p < .001 \)) in KTR. Moreover, KTR were less frequently in need of vasopressor support but were significantly more likely to develop AKI (46.1% vs
TABLE 1  Clinical characteristics, management, and outcomes of matched nontransplant patients and kidney transplant recipients hospitalized for COVID-19

|                          | Nontransplant | Transplant | SMD [95% CI] | N  |
|--------------------------|---------------|------------|--------------|----|
| **Baseline characteristics** |               |            |              |    |
| Median age [IQR], years  | 63.0 [48.0–74.0] | 62.0 [53.0–69.0] | 0.042 [-0.126;0.210] | 546 |
| Age >60 years, n (%)     | 147 (53.8%) | 159 (58.2%) | 0.089 [-0.079;0.256] | 546 |
| Men, n (%)               | 173 (63.4%) | 181 (66.3%) | 0.061 [-0.106;0.229] | 546 |
| Median BMI [IQR], kg/m²  | 27.0 [23.0–30.0] | 26.0 [24.0–30.0] | 0.024 [-0.144;0.192] | 546 |
| BMI >25 kg/m², n (%)     | 181 (66.3%) | 177 (64.8%) | 0.031 [-0.137;0.199] | 546 |
| Hypertension, n (%)      | 136 (49.8%) | 106 (38.8%) | 0.024 [-0.144;0.192] | 546 |
| Cardiovascular disease, n (%) | 106 (38.8%) | 106 (38.8%) | 0.000 [-0.168;0.168] | 546 |
| Respiratory disease, n (%) | 45 (16.5%) | 38 (13.9%) | 0.071 [-0.101;0.239] | 546 |
| Diabetes, n (%)          | 98 (35.9%) | 101 (37.0%) | 0.129 [-0.074;0.315] | 546 |
| Cancer, n (%)            | 26 (9.5%) | 34 (12.5%) | 0.094 [-0.074;0.262] | 546 |
| Smoking, n (%)           | 12 (4.4%) | 28 (12.7%) | 0.301 [0.123;0.480] | 493 |
| **Clinical presentation** |               |            |              |    |
| Anosmia, n (%)           | 24 (11.5%) | 34 (14.1%) | 0.077 [-0.109;0.262] | 449 |
| Cough, n (%)             | 158 (57.9%) | 162 (66.1%) | 0.171 [-0.000;0.343] | 518 |
| Dyspnea, n (%)           | 174 (63.7%) | 123 (45.1%) | 0.382 [0.213;0.551] | 546 |
| Fever, n (%)             | 201 (73.6%) | 199 (80.6%) | 0.166 [-0.000;0.338] | 520 |
| Headache, n (%)          | 47 (17.2%) | 41 (18.3%) | 0.028 [-0.148;0.205] | 497 |
| Diarrhea, n (%)          | 63 (23.1%) | 93 (36.3%) | 0.293 [0.122;0.465] | 529 |
| Time from diagnosis to admission [IQR], days | 7.0 [3.0–9.0] | 5.0 [3.0–8.0] | 0.088 [-0.086;0.262] | 511 |
| **Laboratory data**      |               |            |              |    |
| Median CRP [IQR], mg/L   | 80 [33–148] | 62 [27–118] | 0.143 [-0.044;0.330] | 451 |
| Median lymphocyte count [IQR], G/L | 0.88 [0.65–1.29] | 0.70 [0.41–0.96] | 0.382 [0.193;0.571] | 450 |
| Median platelet count [IQR], G/L | 200 [159–268] | 180 [146–238] | 0.173 [-0.014;0.360] | 453 |
| Thrombocytopenia <150 G/L, n (%) | 57 (22%) | 53 (27%) | 0.129 [-0.058;0.315] | 453 |
| Median creatinine [IQR], µmol/L | 76 [59–99] | 176 [132–259] | 0.945 [0.759;1.131] | 495 |
| **Drug treatment**       |               |            |              |    |
| Azithromycin, n (%)      | 123 (45.1%) | 66 (24.2%) | 0.450 [0.280;0.620] | 546 |
| Other antibiotics, n (%) | 204 (74.7%) | 179 (65.6%) | 0.201 [0.033;0.369] | 546 |
| Antifungal drugs, n (%)  | 7 (2.6%) | 12 (4.4%) | 0.100 [-0.068;0.268] | 546 |
| Remdesivir, n (%)        | 0 (0.0%) | 2 (0.7%) | 0.121 [-0.046;0.289] | 546 |
| Lopinavir/Ritonavir, n (%) | 71 (26.0%) | 15 (5.5%) | 0.387 [0.146;0.758] | 546 |
| Oseltamivir, n (%)       | 2 (0.7%) | 6 (2.2%) | 0.122 [-0.046;0.290] | 546 |
| Hydroxychloroquine, n (%) | 55 (20.1%) | 63 (23.1%) | 0.071 [-0.097;0.239] | 546 |
| Tocilizumab, n (%)       | 3 (1.1%) | 15 (5.5%) | 0.248 [0.080;0.416] | 546 |
| **Outcomes**             |               |            |              |    |
| Bacterial coinfection, n (%) | 169 (61.9%) | 54 (19.8%) | 0.948 [0.772;1.135] | 546 |
| Viral coinfection, n (%)  | 1 (0.4%) | 9 (3.3%) | 0.220 [0.052;0.388] | 546 |
| Fungal coinfection, n (%) | 2 (0.7%) | 11 (4.0%) | 0.218 [0.029;0.386] | 546 |
| Oxygen therapy, n (%)    | 156 (71.2%) | 170 (73.9%) | 0.060 [-0.125;0.245] | 449 |
| Mechanical ventilation, n (%) | 96 (35.2%) | 78 (28.6%) | 0.142 [-0.026;0.310] | 546 |
| Vasopressor support, n (%) | 69 (25.3%) | 36 (13.2%) | 0.310 [0.142;0.479] | 546 |

(Continues)
11.2%, respectively, \( p < .001 \) that would require dialysis (12.7% vs 8.1%, respectively, \( p = .023 \)). The 30-day cumulative incidence of severe COVID-19 and death were similar in the two groups (43.8% vs 41.2%, \( p = .21 \), and 17% versus 16.6%, \( p = .46 \), in nontransplant patients and KTR, respectively; Figure S1A,B).

Owing to the significant differences in age and comorbidities, a further analysis was performed on matched KTR (\( n = 273 \)) and nontransplant patients (\( n = 273 \)). The median follow-up time from admission was 64 days (IQR: 55−71 days) for the entire matched cohort. Specifically, it was 58 days (IQR: 48−67 days) and 67 days (IQR: 62−73 days) for transplant recipients and nontransplant patients, respectively. The characteristics and outcomes of the matched groups are shown in Table 1. The univariable analysis showed that the 30-day cumulative incidence of severe disease was similar in both groups (Figure 1A; 42.2% versus 42.1% in KTR and nontransplant patients, respectively; \( p = .6 \)), whereas the 30-day mortality was significantly higher among KTR (Figure 1B; 17.9% versus 11.4%, respectively; \( p = .038 \)). Risk factors for severe COVID-19 were age >60 years, cardiovascular disease, dyspnea, fever, lymphopenia, and C-reactive protein >60 mg/L (Table 2). Furthermore, age >60 years, hypertension, cardiovascular disease, diabetes, lymphopenia, being a KTR (HR = 1.55, 1.02−2.35), and having a creatinine level >115 µmol/L (HR = 2.32, 1.45−3.70) were associated with mortality (Table 3). In multivariable analysis, cardiovascular disease, dyspnea, and fever were independent risk factors for severe disease. Age >60 years, cardiovascular disease, having dyspnea and fever at admission, and a serum creatinine >115 µmol/L were also independently associated with mortality, whereas being a KTR was not (Table 4). Because the two matched groups were not well balanced in terms of hypertension, we constructed a different model in which this variable was included for matching. However, the results of multivariable analysis were entirely consistent with those reported in the model that did not include hypertension as a matching variable (data not shown).

### DISCUSSION

The present study compared for the first time hospitalized KTR with COVID-19 to a cohort of hospitalized nontransplant patients in order to determine if they would have different outcomes and a higher mortality rate. First, we demonstrated that the entire cohort of KTR hospitalized for COVID-19 exhibited significant differences compared to the nontransplant cohort. Accordingly, KTR were younger (by 7 years) and had a higher burden of comorbidities. As expected, nontransplant patients had a better renal function at admission. This could reflect either the presence of a preexisting

---

**TABLE 1** (Continued)

|                          | Nontransplant | Transplant | SMD [95% CI] | N  |
|--------------------------|---------------|------------|--------------|----|
| Acute kidney injury, n (%) | 36 (13.2%) | 125 (45.8%) | 0.766 [0.592;0.939] | 546 |
| Renal replacement therapy, n (%) | 27 (9.9%) | 36 (13.2%) | 0.103 [−0.065;0.271] | 546 |

Data are expressed as medians (IQRs) or counts (percentages), as appropriate. Patients were matched (1:1 ratio) for age, BMI, cardiovascular and respiratory diseases, cancer, and diabetes.

Abbreviations: BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; ICU, intensive care unit; IQR, interquartile range; RAS, renin-angiotensin system; SMD, standardized mean difference.

---
chronic kidney disease or an AKI in KTR—who were frequently admitted with diarrhea and high fever. Moreover, subsequent AKI and renal replacement therapy occurred more frequently among KTR than in nontransplant patients (46.1% and 11.2%, respectively) during hospitalization. AKI was observed in 5.1% of patients hospitalized with COVID-19 in Cheng et al’s report, 7 and 4.5% of patients in the meta-analysis published by Yang et al. 12 The etiology of AKI during COVID-19 is multifactorial. In addition to SARS-CoV-2’s direct attack of tubular cells via ACE2 receptors, other factors that may contribute to kidney injury include hypoxia, CRS, and a hypercoagulable state. 13 The susceptibility of KTR to dehydration, nephrotoxic drugs, and hemodynamic instability can also explain the high frequency of renal dysfunction in this cohort.

Given the differences between the transplant and nontransplant cohorts’ baseline characteristics, we performed a matched analysis after adjusting for known risk factors of severe COVID-19 and COVID-19-related death 9-11 (i.e., age, BMI, cardiovascular and respiratory diseases, cancer, and diabetes) to minimize the effects of potential confounders. Our results validate the findings from previous studies in nontransplant patients with respect to known risk factors for severe COVID-19 and COVID-19-related death. 14,15 However, being a KTR was not associated with a more frequent need for ICU admission in our study. This could be explained by the shorter time from symptom onset to hospitalization (5 versus 7 days in KTR and nontransplant patients, respectively) and the lower incidence of pulmonary involvement at admission.

| TABLE 2 Risk factors for severe COVID-19 (ICU admission or mechanical ventilation or death) in univariable analysis in matched transplant and nontransplant cohorts (n = 546) |
|---|---|---|---|---|
| Baseline characteristics | | | | |
| Renal transplantation - n (%) | No event | Event | HR | p.ratio |
| N = 314 | N = 232 | | | N |
| 157 (50.0%) | 116 (50.0%) | 0.91 [0.71;1.18] | 0.498 | 546 |
| Median age [IQR] - yr | 60.0 [48.0–70.0] | 65.0 [55.8–73.0] | 1.01 [1.01;1.02] | 0.002 | 546 |
| Age >60 yr - n (%) | 159 (50.6%) | 147 (63.4%) | 1.46 [1.12;1.91] | 0.005 | 546 |
| Male - no.(%) | 194 (61.8%) | 160 (69.0%) | 1.30 [0.99;1.72] | 0.063 | 546 |
| BMI >25 kg/m2 - n (%) | 200 (63.7%) | 158 (68.1%) | 1.20 [0.91;1.59] | 0.187 | 546 |
| Hypertension - n (%) | 207 (68.5%) | 161 (71.6%) | 1.05 [0.78;1.40] | 0.763 | 527 |
| RAS blockers - n (%) | 126 (42.0%) | 89 (40.3%) | 0.92 [0.70;1.20] | 0.534 | 521 |
| Cardiovasc. disease - n (%) | 109 (34.7%) | 103 (44.4%) | 1.35 [1.05;1.76] | 0.022 | 546 |
| Respiratory disease - n (%) | 47 (15.0%) | 36 (15.5%) | 1.04 [0.73;1.49] | 0.819 | 546 |
| Diabetes - n (%) | 102 (32.5%) | 97 (41.8%) | 1.29 [1.00;1.68] | 0.055 | 546 |
| Cancer - n (%) | 37 (11.8%) | 23 (9.91%) | 0.86 [0.56;1.32] | 0.489 | 546 |
| Smoking - n (%) | 25 (8.80%) | 17 (7.18%) | 0.79 [0.46;1.33] | 0.370 | 493 |
| Admission characteristics | | | | |
| Anosmia - n (%) | 40 (15.2%) | 18 (9.68%) | 0.66 [0.40;1.07] | 0.090 | 449 |
| Cough - n (%) | 196 (66.2%) | 124 (55.9%) | 0.74 [0.57;0.96] | 0.025 | 518 |
| Dyspnea - n (%) | 152 (48.4%) | 145 (62.5%) | 1.71 [1.31;2.23] | <0.001 | 546 |
| Fever - n (%) | 216 (72.2%) | 184 (83.3%) | 1.61 [1.13;2.29] | 0.009 | 520 |
| Headache - no.(%) | 57 (20.1%) | 31 (14.6%) | 0.73 [0.50;1.07] | 0.109 | 497 |
| Diarrhea - n (%) | 90 (29.4%) | 66 (29.6%) | 1.00 [0.75;1.33] | 0.995 | 529 |
| Time from diag. to admission [IQR] - d | 6.00 [3.00–9.00] | 6.00 [3.00–8.00] | 0.99 [0.96;1.02] | 0.473 | 511 |
| Biological data | | | | |
| CRP >60 mg/l - n (%) | 119 (45.6%) | 135 (71.1%) | 2.54 [1.86;3.48] | <0.001 | 451 |
| Median lymphocyte count [IQR] - G/l | 0.85 [0.58–1.21] | 0.75 [0.50–1.03] | 0.74 [0.57;0.98] | 0.035 | 450 |
| Median platelet count [IQR] - G/l | 189 [148–257] | 197 [153–257] | 1.00 [1.00;1.00] | 0.548 | 453 |
| Thrombocytopenia <150 G/l - no.(%) | 65 (25.3%) | 45 (23.0%) | 0.89 [0.64;1.24] | 0.502 | 453 |
| Median Scr [IQR] - µmol/l | 102 [66.7–176] | 127 [77.0–204] | 1.00 [1.00;1.00] | 0.373 | 495 |
| Scr >115 µmol/l | 129 (46.7%) | 118 (53.9%) | 1.15 [0.88;1.50] | 0.292 | 495 |

Note. Patients were matched (1:1 ratio) for age, BMI, cardiovascular and respiratory diseases, cancer, and diabetes. Data are expressed as medians (IQRs) or counts (percentages), as appropriate.

Abbreviations: BMI, body mass index; cardiovasc, cardiovascular; CRP, C-reactive protein; diag, diagnosis; HR, hazard ratio; IQR, interquartile range; RAS, renin-angiotensin system; Scr, serum creatinine.
However, the comparison of matched cohorts also showed that KTR had a twofold higher risk of COVID-19-related death compared to nontransplant patients after adjustment for age, BMI, and major comorbidities. While previous studies have shown that transplantation is a risk factor for mortality, a direct matched comparison between transplanted and nontransplant patients had never been performed. Data from a very large cohort of 17 million patients indicated that organ transplant recipients had an adjusted 3.55-fold higher risk of death, whereas those with glomerular filtration rates below 30 mL/min had a 2.5-fold increased risk.\textsuperscript{16} In Cheng et al’s cohort,\textsuperscript{7} the incidence of in-hospital death in patients with increased baseline serum creatinine was 33.7%, which was higher than in those with normal creatinine levels (13.2%). Notably, this difference persisted after adjusting for age and comorbidities. In prior studies focusing on respiratory viruses (H1N1, SARS, and MERS-CoV),\textsuperscript{17,18} kidney injury was also associated with an increased risk of death. It remains uncertain whether the higher mortality rate observed in KTR is caused by immunosuppression and/or the increased rate of renal dysfunction. Multivariable analysis revealed that being a KTR was not independently associated with mortality, whereas a serum creatinine $>115$ µmol/L was retained in the model as an independent risk factor for death. These results indicate a prominent role for renal failure as a driver of COVID-19-related mortality.

Our findings need to be interpreted in the context of some limitations. First, one may argue that the comparability between a multicenter French nationwide transplant cohort and a single-center

### Table 3: Risk factors for death in univariable analysis in the matched transplant and nontransplant cohorts ($n = 546$)

|                         | No event | Event | HR     | p.ratio | N   |
|-------------------------|----------|-------|--------|---------|-----|
| **Baseline characteristics** |          |       |        |         |     |
| Renal transplantation - n (%) | 218 (48.0%) | 55 (59.8%) | 1.55 [1.02;2.35] | 0.039 | 546 |
| Median age [IQR] - yr   | 60.0 [50.0–69.0] | 71.0 [62.0–79.2] | 1.05 [1.04;1.07] | <0.001 | 546 |
| Age >60 yr - n (%)      | 232 (51.1%) | 74 (80.4%) | 3.61 [2.16;6.05] | <0.001 | 546 |
| Male - n (%)            | 295 (65.0%) | 59 (64.1%) | 0.97 [0.63;1.49] | 0.891 | 546 |
| BMI >25 kg/m2 - n (%)   | 298 (65.6%) | 60 (65.2%) | 1.00 [0.65;1.53] | 0.994 | 546 |
| Hypertension - n (%)    | 298 (67.9%) | 70 (79.5%) | 1.76 [1.05;2.95] | 0.033 | 527 |
| RAS blockers - n (%)    | 177 (40.6%) | 38 (44.7%) | 1.16 [0.76;1.78] | 0.492 | 521 |
| Cardiovasc disease - n (%) | 160 (35.2%) | 52 (56.5%) | 2.23 [1.47;3.36] | <0.001 | 546 |
| Resp. disease - n (%)   | 70 (15.4%) | 13 (14.1%) | 0.91 [0.51;1.64] | 0.760 | 546 |
| Diabetes - n (%)        | 154 (33.9%) | 45 (48.9%) | 1.75 [1.16;2.64] | 0.007 | 546 |
| Cancer - n (%)          | 51 (11.2%) | 9 (9.78%) | 0.86 [0.43;1.71] | 0.668 | 546 |
| Smoking - n (%)         | 32 (7.75%) | 8 (10.0%) | 1.27 [0.61;2.64] | 0.519 | 493 |
| **Admission characteristics** |          |       |        |         |     |
| Anosmia - no.(%)        | 55 (14.2%) | 3 (4.84%) | 0.33 [0.10;1.05] | 0.060 | 449 |
| Cough - no.(%)          | 274 (63.3%) | 46 (54.1%) | 0.71 [0.46;1.09] | 0.118 | 518 |
| Dyspnea - n (%)         | 240 (52.9%) | 57 (62.0%) | 1.45 [0.95;2.20] | 0.086 | 546 |
| Fever - no.(%)          | 330 (75.9%) | 70 (82.4%) | 1.47 [0.84;2.56] | 0.179 | 520 |
| Headache - n (%)        | 76 (18.2%) | 12 (15.0%) | 0.82 [0.44;1.51] | 0.524 | 497 |
| Diarrhea - no.(%)       | 135 (30.5%) | 21 (24.4%) | 0.76 [0.46;1.24] | 0.275 | 529 |
| Time from diag. to admission [IQR] - d | 6.00 [3.00–9.00] | 4.00 [2.00–7.00] | 0.94 [0.89;0.99] | 0.018 | 511 |
| **Biological data**     |          |       |        |         |     |
| CRP >60 mg/l - n (%)    | 207 (54.0%) | 47 (69.1%) | 1.84 [1.10;3.08] | 0.020 | 451 |
| Median lymphocyte count [IQR] - G/l | 0.80 [0.57–1.18] | 0.71 [0.45–0.96] | 0.43 [0.24;0.77] | 0.005 | 450 |
| Median platelet count [IQR] - G/l | 190 [150–253] | 201 [153–259] | 1.00 [1.00;1.00] | 0.526 | 453 |
| Thrombopenia <150 G/l - n (%) | 93 (24.7%) | 17 (22.4%) | 0.87 [0.51;1.49] | 0.604 | 453 |
| Median Scr [IQR] - µmol/l | 102 [69.7–179] | 151 [100–219] | 1.00 [1.00;1.00] | 0.029 | 495 |
| Scr >115 µmol/l         | 192 (46.4%) | 55 (67.9%) | 2.32 [1.45;3.70] | <0.001 | 495 |

Patients were matched (1:1 ratio) for age, BMI, cardiovascular and respiratory diseases, cancer, and diabetes. Abbreviations: BMI, body mass index; cardiovasc, cardiovascular; CRP, C-reactive protein; diag, diagnosis; HR, hazard ratio; IQR, interquartile range; RAS, renin-angiotensin system; Scr, serum creatinine.

Data are expressed as medians (IQRs) or counts (percentages), as appropriate.
cardiovascular and respiratory diseases, cancer, and diabetes. Concordance for the severe disease model: 0.63; concordance for the mortality model: 0.73. Patients were matched (1:1 ratio) for age, BMI, diabetes, and hypertension. The control group was low. Nevertheless, the single-center control group was large and representative of a different range of settings (i.e., medical, surgical, and ICU departments). Second, we are aware that KTR and control patients were managed differently—which can represent a potential source of confounding when their clinical outcomes are analyzed. While baseline lymphocyte count and creatinine concentrations were available for KTR, the majority of nontransplant patients had a negative clinical history before the onset of COVID-19. Therefore, we were unable to provide data on these parameters in nontransplant patients. Finally, all of the study patients were hospitalized. Thus, the question as to whether our findings are generalizable to an outpatient setting remains answered. These caveats notwithstanding, this study is the largest to date to comprehensively compare the clinical features and outcomes of COVID-19 in KTR with respect to nontransplant patients.

In summary, our study shows that, after adjustment for potential confounders, KTR with COVID-19 had a higher mortality rate than nontransplant patients, despite a similar occurrence of severe disease. While preexistent chronic kidney disease or AKI might have a greater prognostic impact than the immunosuppression state, further research is needed to shed more light on this issue.

ACKNOWLEDGMENT

This study was supported by the Strasbourg University Hospital (COVIS-HUS Study- HUS number 7760)

DISCLOSURE

The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Sophie Caillard https://orcid.org/0000-0002-0525-4291
Nathalie Chavarot https://orcid.org/0000-0001-6361-1392
Marie Matignon https://orcid.org/0000-0001-7704-427X

Nassim Kamar https://orcid.org/0000-0003-1930-8964
Olivier Thaunat https://orcid.org/0000-0002-3648-8963
Renaud Sanoujd https://orcid.org/0000-0002-6657-6235
Dominique Bertrand https://orcid.org/0000-0002-8766-4859
Christophe Masset https://orcid.org/0000-0002-7442-2164
Lionel Couzi https://orcid.org/0000-0002-9213-6196
Jonathan M. Chemouny https://orcid.org/0000-0001-6309-3986
Antoine Durrbach https://orcid.org/0000-0003-0385-8726
Dany Anglicheau https://orcid.org/0000-0001-5793-6174
Ilies Benotmane https://orcid.org/0000-0001-9113-2479
Yannick LeMeur https://orcid.org/0000-0001-8913-415X

REFERENCES

1. Kumar D, Tellier R, Draker R, Levy G, Humar A. Severe Acute Respiratory Syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening. Am J Transplant. 2003;3(8):977-981.
2. AlGhamdi M, Mushtaq F, Awn N, Salihou S. MERS CoV infection in two renal transplant recipients: case report. Am J Transplant. 2015;15(4):1101-1104.
3. Akalin E, Azizi Y, Bartash R, et al. COVID-19 and kidney transplantation. N Engl J Med. 2020;382(25):2475-2477.
4. Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid transplant organ recipients: initial report of the US epicenter. Am J Transplant. 2020;20(7):1800-1808.
5. Alberici F, Delbarba E, Manenti C, et al. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. Kidney Int. 2020;97(6):1083-1088.
6. Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036-1045.e9.
7. Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829-838.
8. Ho D, Imai K, King G, Stuart EA. MatchIt: Nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42(8):1-28.
9. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care. 2020;24(1):108.
10. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062.

TABLE 4 Multivariable analysis of risk factors for severe disease and mortality in matched transplant and nontransplant cohorts (n = 546)

| Severe disease | HR     | p     | Mortality | HR     | p     |
|---------------|--------|-------|-----------|--------|-------|
| Cardiovasc disease | 1.35 [1.03:1.76] | .028  | Cardiovasc disease | 1.54 [0.96:2.46] | .071  |
| Cough         | 0.61 [0.46:0.80] | <.001 | Cough      | 0.58 [0.36:0.92] | .022  |
| Dyspnea       | 1.90 [1.43:2.53] | .004  | Dyspnea    | 1.74 [1.08:2.78] | .022  |
| Fever         | 1.70 [1.19:1.76] | .004  | Fever      | 1.81 [1.00:3.28] | .050  |
| SCr >115 µmol/L | 2.40 [1.48:3.87] | <.001 | Age >60 years | 3.47 [1.86:6.47] | <.001 |

Concordance for the severe disease model: 0.63; concordance for the mortality model: 0.73. Patients were matched (1:1 ratio) for age, BMI, diabetes, and hypertension. The control group is low. Nevertheless, the single-center control group was large and representative of a different range of settings (i.e., medical, surgical, and ICU departments). Second, we are aware that KTR and control patients were managed differently—which can represent a potential source of confounding when their clinical outcomes are analyzed. While baseline lymphocyte count and creatinine concentrations were available for KTR, the majority of nontransplant patients had a negative clinical history before the onset of COVID-19. Therefore, we were unable to provide data on these parameters in nontransplant patients. Finally, all of the study patients were hospitalized. Thus, the question as to whether our findings are generalizable to an outpatient setting remains answered. These caveats notwithstanding, this study is the largest to date to comprehensively compare the clinical features and outcomes of COVID-19 in KTR with respect to nontransplant patients.

In summary, our study shows that, after adjustment for potential confounders, KTR with COVID-19 had a higher mortality rate than nontransplant patients, despite a similar occurrence of severe disease. While preexistent chronic kidney disease or AKI might have a greater prognostic impact than the immunosuppression state, further research is needed to shed more light on this issue.

ACKNOWLEDGMENT

This study was supported by the Strasbourg University Hospital (COVIS-HUS Study- HUS number 7760)

DISCLOSURE

The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Sophie Caillard https://orcid.org/0000-0002-0525-4291
Nathalie Chavarot https://orcid.org/0000-0001-6361-1392
Marie Matignon https://orcid.org/0000-0001-7704-427X
11. Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. PLoS Med. 2020;17(9):e1003321.

12. Yang X, Jin Y, Li R, Zhang Z, Sun R, Chen D. Prevalence and impact of acute renal impairment on COVID-19: a systematic review and meta-analysis. Crit Care. 2020;24(1):356.

13. Naicker S, Yang CW, Hwang SJ, Liu BC, Chen JH, Jha V. The novel coronavirus 2019 epidemic and kidneys. Kidney Int. 2020;97(5):824-828.

14. Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. Crit Care. 2020;24(1):179.

15. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region. Italy. JAMA. 2020;323(16):1574-1581.

16. Williamson EJ, Walker AJ, Bhaskanan K. OpenSAFELY: factors associated with COVID-19 death in 17 million patients [published online ahead of print July 8, 2020]. Nature. https://doi.org/10.1038/s41586-020-2521-4

17. Chu KH, Tsang WK, Tang CS, et al. Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. Kidney Int. 2005;67(2):698-705.

18. Jung JY, Park BH, Hong SB, et al. Acute kidney injury in critically ill patients with pandemic influenza A pneumonia 2009 in Korea: a multicenter study. J Crit Care. 2011;26(6):577-585.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Caillard S, Chavarot N, Francois H, et al. Is COVID-19 infection more severe in kidney transplant recipients?. Am J Transplant. 2021;21:1295-1303. https://doi.org/10.1111/ajt.16424

APPENDIX
FRENCH SOT COVID REGISTRY
Sophie CAILLARD, Bruno MOULIN, Service de Néphrologie et Transplantation, Hôpitaux Universitaires de Strasbourg, STRASBOURG; Samira FAFI-KREMER, Laboratoire de Virologie, Hôpitaux Universitaires de Strasbourg, STRASBOURG; Marc HAZZAN, Service de Néphrologie, Hôpital Huriez, LILLE; ANGLICHEAU Dany, Service de Néphrologie et Transplantation Adultes, AP-HP, Hôpital Necker, PARIS; Alexandre HERTIG, Jérôme TOURRET, Benoît BARROU, Service de Néphrologie, AP-HP, Hôpital La Pitié Salpêtrière, PARIS; Emmanuel MORELON, Olivier THAUNAT, Service de Néphrologie, Hôpital Edouard Herriot, LYON; Lionel COUZI, Pierre MERVILLE, Service de Néphrologie – Transplantation – Dialyse, Hôpital Pellegrin, BORDEAUX; Valérie MOAL, Tristan LEGRIS, Service de Néphrologie et Transplantation, AP-HM, Hôpital de la Conception, MARSEILLE; Pierre-François WESTEEL, Maité JAUREGUY, Service de Néphrologie, CHU Amiens Picardie, AMIENS; Luc FRIMAT, Service de Néphrologie, CHRU Nancy, VANDOEUVRE; Didier DUCLOUX, Jamal BAMOULID, Service de Néphrologie, Hôpital Jean-Minjoz, BESANCON; Dominique BERTRAND, Service de Néphrologie, CHU de Rouen, ROUEN; Michel TSIMARATOS, Florentine GARAIX-GILARDO, Service de Pédiatrie multidisciplinaire, Hôpital La Timone, MARSEILLE; Jérôme DUMORTIER, Service d’Hépato-Gastro-entérologie, Hôpital Edouard Herriot, LYON; Sacha MUSSTOZ, Antoine ROUX, Centre chirurgical Marie Lannelongue, LE PLESSIS ROBINSON; Laurent SEBBAG, Service d’insuffisance cardiaque, Hôpital Louis Pradel, BRON; Yannick LE MEUR, Service de Néphrologie, Hôpital de la cauvel blanche, BREST; Gilles BLANCHO, Christophe MASSET, Service de Néphrologie – Transplantation, Hôtel Dieu, NANTES; Nassim KAMAR, Service de Néphrologie et Transplantation, Hôpital Rangueil, TOULOUSE; Hélène FRANCOIS, Éric Rondeau, Service de Néphrologie, Dialyse et Transplantation, AP-HP, Hôpital Tenon, PARIS; Nicolas BOUVIER, Service de Néphrologie, Dialyse, Transplantation rénale, CHU, CAEN; Christiane MOUSSON, Service de Néphrologie, DJON; Matthias BUCHLER, Philippe GATAULT, Service de Néphrologie, TOURS; Jean-François AUGUSTO, Agnès DUVEAU, Service de Néphrologie, Dialyse, Transplantation, CHU Angers, ANGERS; Cécile VIGNEAU, Marie-Christine MORIN, Jonathan CHEMOUNY, Leonard GOLBIN, Service de Néphrologie, CHU de Rennes, RENNES; Philippe GRIMBERT, Marie MATIGNON, Antoine DURRBACH, Service de Néphrologie, Hôpital Henri-Mondor, CRETEIL; Clarisse GREZE, Service de Néphrologie, AP-HP, Hôpital Bichat Claude Bernard, PARIS; Renaud SNANOUDJ, Service de Néphrologie, Hôpital Foch., Service de Néphrologie et Transplantation Hôpital du Kremlin Bicêtre, LE KREMLIN BICETRE; Charlotte COLOSIO, Betoul SCHVARTZ, Service de Néphrologie, Hôpital Maiso Blanche, REIMS; Paolo MALVEZZI, Service de Néphrologie, Hémodialyse, Transplantation rénale, Hôpital La Tronche, GRENOBLE; Christophe MARIAT, Service de Néphrologie, CHU de Saint Etienne, SAINT ETIENNE; Antoine THIERRY, Service de Néphrologie, Hémodialyse et Transplantation rénale, Hôpital Jean Bernard, POITIERS; Moulie LE QUINTREC, Service de Néphrologie-Transplantation-Dialyse, CHU Lapeyronie, MONTPELLIER; Antoine SICARD, Service de Néphrologie, Hôpital Pasteur, NICE; Jean Philippe REROLLE, Service de Néphrologie, CHU Dupuytren, LIMOGES; Anne-Élisabeth Heng, Cyril GARROUSTE, Service de Néphrologie, CHU de Rouen, ROUEN; Michel TSIMARATOS, Florentine GARAIX-GILARDO, Service de Néphrologie, CHU de La Réunion, SAINT DENIS; Éric EPAILLY, service de cardiologie, Hôpitaux Universitaires de Strasbourg, STRASBOURG; Olivier BRUGIERE, Service d’hématologie, Hôpital Foch, SURESNES; Sébastien DHARRANCY, Service d’hématologie, Hôpital Huriez, LILLE; Éphrem SALAME, service de chirurgie hépato-gastro-entérologie, Hôpital Universitaire de Tours, TOURS; Faouzi SALIBA, service d’hématologie, Centre hépato-biliaire Paul Brousse, VILLEJUIF.